Research News
The latest news and featured articles about blood cancer research supported by LLS
Research News
The latest news and featured articles about blood cancer research supported by LLS
Please visit the main LLS News page for all blood cancer updates including patient care, advocacy and fundraising.
For the latest from LLS Research please follow us on Twitter:
Latest Tweets by LLSResearch
Some of our latest news:
FDA Approves New Formulation of Important Childhood Leukemia Drug
The U.S. Food and Drug Administration yesterday approved nelarabine injection, a critical treatment for T-cell acute lymphoblastic leukemia (T-ALL), an aggressive blood cancer that is most common in children.
Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-mutant AML
SAN DIEGO, Feb. 09, 2023 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patients have been dosed in its KOMET-001 Phase 2 registration-directed trial of ziftomenib, the Company’s novel menin inhibitor, in patients with NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).
Exciting new publications supported by LLS: March 2022
Editor's Choice: three peer reviewed and LLS supported publications from Spring 2022